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Abstract
Background: Expression of active c-Abl in adult mouse forebrain neurons in the AblPP/tTA mice resulted in severe
neurodegeneration, particularly in the CA1 region of the hippocampus. Neuronal loss was preceded and
accompanied by substantial microgliosis and astrocytosis. In contrast, expression of constitutively active Arg
(Abl-related gene) in mouse forebrain neurons (ArgPP/tTA mice) caused no detectable neuronal loss or gliosis,
although protein expression and kinase activity were at similar levels to those in the AblPP/tTA mice.
Methods: To begin to elucidate the mechanism of c-Abl-induced neuronal loss and gliosis, gene expression
analysis of AblPP/tTA mouse forebrain prior to development of overt pathology was performed. Selected results
from gene expression studies were validated with quantitative reverse transcription PCR , immunoblotting and
bromodeoxyuridine (BrdU) labeling, and by immunocytochemistry.
Results: Two of the top pathways upregulated in AblPP/tTA mice with c-Abl expression for 2 weeks were cell cycle
and interferon signaling. However, only the expression of interferon signaling pathway genes remained elevated at
4 weeks of c-Abl induction. BrdU incorporation studies confirm that, while the cell cycle pathway is upregulated in
AblPP/tTA mice at 2 weeks of c-Abl induction, the anatomical localization of the pathway is not consistent with
previous pathology seen in the AblPP/tTA mice. Increased expression and activation of STAT1, a known component
of interferon signaling and interferon-induced neuronal excitotoxicity, is an early consequence of c-Abl activation in
AblPP/tTA mice and occurs in the CA1 region of the hippocampus, the same region that goes on to develop
severe neurodegenerative pathology and neuroinflammation. Interestingly, no upregulation of gene expression of
interferons themselves was detected.
Conclusions: Our data suggest that the interferon signaling pathway may play a role in the pathologic processes
caused by c-Abl expression in neurons, and that the AblPP/tTA mouse may be an excellent model for studying
sterile inflammation and the effects of interferon signaling in the brain.
Introduction
The tyrosine kinase c-Abl has been shown to co-localize
with tangles, plaques, and granulovacuolar degeneration
in Alzheimer’s disease (AD) [1]. The c-Abl kinase also
phosphorylates tau, the amyloid precursor protein (APP)
and Fe65, an adaptor protein thought to play a role in
APP processing [2-6]. The c-Abl tyrosine kinase has
been shown to be activated by oxidative stress and
treatment with Aβ peptides in neurons in culture [7].
These known activators of c-Abl are associated with
aging and AD and, together with data showing c-Abl ac-
tivation and co-localization with the characteristic
lesions of AD, suggest that c-Abl may be activated dur-
ing aging and neurodegenerative disease. The AblPP/
tTA mouse model, which expresses an inducible, consti-
tutively active form of c-Abl under the CamKIIα pro-
moter using the Tet-Off system, was created to
investigate the effects of c-Abl expression in adult fore-
brain neurons. The AblPP/tTA mouse develops progres-
sive neurodegeneration and neuroinflammation in the
CA1 region of the hippocampus, indicating that
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activation of c-Abl alone in adult neurons is sufficient to
cause neuronal loss and inflammation [8].
Aberrant cell cycle activation has been shown to occur
in neurons in human AD prior to neuronal death [9-13],
and cell cycle events have been shown to precede amyl-
oid deposition and microglial activation in several mouse
models of AD [14]. Additionally, mice expressing a
transgene that forces postmitotic neurons into the cell
cycle recapitulate all the major pathological hallmarks of
AD – neurodegeneration, neurofibrillary tangles, and
amyloid plaques [15]. Chronic neuroinflammation and
upregulation of a multitude of cytokines has been shown
to occur in AD [16-26]. Others have suggested that
stress/death signals produced by neurons may be the im-
petus for chronic inflammation in the brain [19,27].
Previously, the pathways that might be induced by c-
Abl activity in neurons were unknown. In an effort to
elucidate these pathways, we performed gene expression
analysis on the forebrains of young AblPP/tTA mice at 2
or 4 weeks offf doxycycline. The expression of thousands
of genes was altered in the AblPP/tTA mouse brain, and
we chose to focus on two of the top pathways found to
be upregulated in the AblPP/tTA mouse: cell cycle and
interferon signaling. We show the anatomic location of
the induction of cell cycle and interferon stimulated
genes in the AblPP/tTA mouse brain, and that changes
in interferon-stimulated gene expression occurred in
neurons and co-localized in the CA1 region of the
hippocampus, which was previously shown to develop
severe neuronal loss and neuroinflammation. These data
suggest that c-Abl expression in neurons can stimulate
interferon signaling in the brain, and that this pathway




Cohorts of five to six AblPP/tTA mice [8] and five to six
wild-type littermates were used. Additional control mice
carried either the CamKII-tTA gene alone or the c-Abl
transgene alone. There was no elevation of c-Abl activity
in these single transgenic mice. All mice were kept on a
diet containing 200 mg/kg doxycycline (Bio-Serv French-
town, NJ 08825) throughout breeding, pregnancy, and
weaning. Animals were housed in a facility with a 12-hour
light/dark cycle and were provided with free access to
water and food at all times. Mice were taken off doxycyc-
line at approximately 4 weeks of age in order to induce c-
Abl expression. Mice were euthanized with isofluorane
and decapitated. Brains were hemisected sagitally. For all
experiments, one half of the forebrain (randomly selected)
was homogenized and frozen, while the other half was
used for microarray analysis, quantitative reverse tran-
scription PCR (qPCR), or immunohistochemistry.
Gene expression analysis
Cohorts of six AblPP/tTA, six wild-type littermates, six
c-Abl, and six CamKII-tTA mice at 2 or 4 weeks off
doxycycline were used for gene expression analysis. The
forebrain of one hemisphere was dissected away from
hindbrain and frozen at −80°C prior to RNA extraction.
Total RNA from mouse brain was extracted using stand-
ard protocols [28]. Total RNA was extracted with an
RNeasy kit Valencia, CA 91355 , and RNA was measured
for quality using an Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA, USA). Reverse transcription
was performed using an ArrayScriptTM reverse tran-
scriptase and T7-Oligo (dT)24 primers, followed by
second-strand synthesis to generate double-stranded
cDNA. The cDNA was converted to biotin-labeled cRNA
(TotalprepTM RNA Labeling Kit, Ambion), then hybri-
dized to the microarray platform. Mouse WG-6 Expres-
sion BeadChip (Illumina, San Diego, CA, USA) with
45,281 probes was the microarray platform used. Micro-
arrays were utilized according to the manufacturer’s
guidelines (Illumina).
Data was analyzed using the BeadStudio software (Illu-
mina) and BRB Array Tools 3.8, a statistical software
package designed for microarray analysis developed by
the National Institutes of Health (linus.nci.nih.gov/BRB-
ArrayTools.html). Expression differences were consid-
ered statistically significant if their P values were less
than 0.001 using an F-test. Ingenuity Pathways Analysis
application was used to determine which biological path-
ways were most upregulated in the AblPP/tTA mouse
based on statistically significant changes in gene expres-
sion. The online database Interferome [29] was used to
identify interferon signaling genes.
Quantitative PCR
qPCR was performed according to standard protocols
[30]. Briefly, total RNA extraction was performed using
TRIzol reagent (Invitrogen) on hippocampus or cortex
of cohorts of five AblPP/tTA mice and five wild-type
controls at 2 weeks off doxycyline and 4 weeks off doxy-
cycline according to manufacturer’s instructions. RNA
was measured for quality using a NanoDrop. A SYBR-
Green PCR mix was used to conduct qPCR with the
ABI Prism 7900HT (Applied Biosystems). β-actin was
used as an internal control, and each assay was per-
formed in triplicate. Primers used for qPCR are listed in
Table 1. The median value of the replicates for each
sample was calculated and expressed as the cycle thresh-
old (CT). ΔCT was calculated as CT of β-actin minus the
CT of the gene of interest in each sample. The relative
amount of target gene expression in each sample was
calculated as 2ΔCT, and fold change was calculated by
dividing 2ΔCT of the gene of interest by 2ΔCT of the gene
in the control sample.
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Antibodies
Antibodies used for immunoblotting and immunohisto-
chemistry are listed in Table 2.
Western blotting
Forebrain homogenates of AblPP/tTA mice and wild-type
controls were used. Forebrain samples were homogenized
in homogenization buffer (TBS with 10 mM NaF, 1 mM
Na3VO4, 2 mM EGTA) with complete Mini protease
inhibitors (Roche), frozen at −80°C, thawed, and spun at
14,000 rpm for 10 minutes at 4°C. Supernatants were
analyzed in all experiments by immunoblotting using
SDS-PAGE, according to standard protocols. Protein con-
centrations were normalized prior to use and all western
blots were normalized to β-actin loading controls.
Bromodeoxyuridine labeling
Bromodeoxyuridine (BrdU), 0.5 mg/ml, was administered
to cohorts of three AblPP/tTA mice and three wild-type
controls in drinking water for 5 days. Mice were eutha-
nized immediately or allowed to age for 4 weeks. For de-
tection of BrdU incorporation, one hemisphere of the
brain was fixed overnight in 4% paraformaldehyde, em-
bedded in paraffin, and sectioned in 5 μm increments.
After rehydration, sections were steamed in 10 mM citrate
buffer for 20 minutes. Endogenous peroxidase activity was
blocked with 3% H2O2 for 10 minutes at room
temperature. Sections were then treated with 3 N HCl for
30 minutes at room temperature and blocked in 5% goat
serum/2% BSA for 1 hour. Primary antibody (anti-BrdU;
Roche) was diluted in blocking solution and sections were
incubated overnight at 4°C. Biotinylated secondary antibody
was applied for 2 hours at room temperature, followed by
streptavidin-HRP for 1 hour at room temperature. A solu-
tion of 20% Superblock (ThermoScientific) in TBS+0.05%
Triton X100 was used as a diluent for the secondary anti-
body and streptavidin-HRP. Staining was visualized with
diaminobenzidine.
Immunohistochemistry
Hemisected brains were fixed overnight in 4% parafor-
maldehyde and cut sagitally into 50 μm sections using a
vibratome. Standard immunohistochemistry protocols
were used. Endogenous peroxidase was blocked using
3% H2O2 in 0.25% TritonX 100 in TBS for 30 minutes at
room temperature. Five percent milk/TBS was used as a
blocking agent and primary antibody diluent. Sections
were blocked for 1 hour at room temperature and incu-
bated in primary antibody at 4°C overnight. After wash-
ing, biotinylated secondary antibody was applied for
2 hours at room temperature. Washes were repeated,
and sections were incubated with Streptavidin-HRP for
1 hour at room temperature. A solution of 20% Superb-
lock (Thermoscientific, Rockford, IL 61101) in TBS+
0.05% Triton X100 was used as a diluent for the secondary
antibody and streptavidin-HRP. Staining was visualized
with diaminobenzidine.
Immunofluorescence
Endogenous peroxidase activity in vibratome sections of
AblPP/tTA and wild-type control mouse brains was
Table 1 Antibodies (IHC= immunohistochemistry,
IHC-P = immunohistochemistry, paraffin sections;
WB= immunoblot)
Epitope Antibody Application Source
BrdU 1170376 IHC-P, 1:400 Roche
Cyclin B1 4135 WB, 1:1000 Cell Signaling Technology
Cyclin D1 2926 WB, 1:1000 Cell Signaling Technology
Cdk4 2906 WB, 1:1000 Cell Signaling Technology
Cdk2 2546 WB, 1:1000 Cell Signaling Technology
Polo-like kinase 1 05-844 WB, 1:1000 Millipore
Stat1 9172S WB, 1:1000 Cell Signaling Technology
IHC, 1:500
Stat1 pY701 9167S WB, 1:1000 Cell Signaling Technology
IHC, 1:250
Stat1 pS727 9177 s WB, 1:1000 Cell Signaling Technology
BrdU, bromodeoxyuridine.
Table 2 Primers
Gene Primer sequences Source
IFNα F: GGATGTGACCTTCCTCAGACTC OriGene
R: ACCTTCTCCTGCGGGAATCCAA
IFNβ F: CAGCTCCAAGAAAGGACGAAC qPrimerDepot
R: GGCAGTGTAACTCTTCTGCAT
IFNγ F: GCGGCCTAGCTCTGAGACAA Primer3
R: GACTGTGCCGTGGCAGTAAC
IL-6 F : ATGGATGCTACCAAACTGGAT RTPrimerDB
R : TGAAGGACTCTGGCTTTGTCT
IP10 F : TCCTTGTCCTCCCTAGCTCA RTPrimerDB
R : ATAACCCCTTGGGAAGATGG
IFIT3 F: GCTCAGGCTTACGTTGACAAGG OriGene
R: CTTTAGGCGTGTCCATCCTTCC
IRF1 F: TCCAAGTCCAGCCGAGACACTA OriGene
R: ACTGCTGTGGTCATCAGGTAGG
Isg15 F: CATCCTGGTGAGGAACGAAAGG OriGene
R: CTCAGCCAGAACTGGTCTTCGT
PSMB8 F: CCTTACCTGCTTGGCACCATGT OriGene
R: TTGGATGCTGCAGACACGGAGA
Stat1 F: GCCTCTCATTGTCACCGAAGAAC OriGene
R: TGGCTGACGTTGGAGATCACCA
β-actin F: TGCACCACCAACTGCTTAG Primer3
R: GGATGCAGGGATGATGTTC
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blocked by 3% H2O2 in 0.25% TritonX 100 in TBS for
30 minutes at room temperature. Blocking solution and
primary antibody diluent was 5% milk. Sections were
blocked for 1 hour at room temperature and incubated
in primary antibodies at 4°C overnight. Biotinylated or
fluorescently conjugated secondary antibody in 20%
Superblock (ThermoScientific) in TBS + 0.05% Tri-
tonX100 was applied for 2 hours at room temperature.
Sections were washed and incubated in Alexafluor con-
jugated streptavidin for 1 hour at room temperature and
mounted on microscope slides. Secondary antibodies
and streptavidin-HRP were diluted in 20% Superblock
(ThermoScientific) in TBS + 0.05% TritonX100. Sections
were incubated in 0.3% Sudan Black in 70% EtOH for
10 minutes at room temperature. Finally, slides were
cover-slipped using ProlongW Gold anti-fade reagent
with DAPI (Invitrogen). A Leica SP2 Scanning Laser
Confocal Microscope was used to visualize fluorescence.
Results
Identification of two pathways induced by c-Abl
activation in mouse forebrain
More than 6,000 genes were found to have significant
changes in expression in the AblPP/tTA mice at 2 weeks
off doxycyline versus wild-type controls, and more than
2,000 genes were found to have significant changes in
expression in AblPP/tTA mice at 4 weeks off doxycyline.
We used Ingenuity Pathways Analysis to determine the
top pathways upregulated in AblPP/tTA mice versus
wild-type mice at 2 and 4 weeks off doxycyline. Two of
the top pathways that were shown to be upregulated in
forebrains of AblPP/tTA mice were cell cycle and inter-
feron signaling.
Cell cycle activation in the AblPP/tTA mouse
Genes in the cell cycle pathway were strongly upregu-
lated in AblPP/tTA mouse forebrain at 2 weeks off doxy-
cyline, but no significant upregulation was present for
any of the cell cycle-related genes at 4 weeks off doxycy-
line. Fold-change values of cell cycle genes in AblPP/
tTA mice at 2 weeks off doxycycline are listed in Table 3.
On immunoblot analysis, increases in polo-like kinase 1
(PLK-1), cyclin B1, and CDK 4 protein levels in forebrain
homogenates at 2 weeks off doxycyline are apparent;
however, levels of CDK 4 and cyclin B1 decrease at
4 weeks off doxycyline (Figure 1). Increases in PLK1
were evident on immunoblots at 4 weeks off doxicycline,
but mRNA levels were not significantly elevated at this
time point, as stated above. No changes in cyclin D1 or
CDK 2 protein levels were observed (data not shown).
Because immunoblot analysis could only be performed
on whole forebrain homogenate, BrdU incorporation
studies were undertaken in order to pinpoint which ana-
tomical regions of the forebrain were experiencing cell
cycle activation. Transgenic mice and controls were
separated into three groups. Cohort A was administered
BrdU for 5 days prior to euthanization at 2 weeks off
doxycyline, cohort B was administered BrdU for 5 days
prior to euthanization at 4 weeks off doxycyline, and co-
hort C was administered BrdU for 5 days at the same
time off doxycyline as cohort A (beginning at about
1 week off doxycyline until 2 weeks off doxycyline) but
allowed to age to 6 weeks off doxycyline. Surprisingly,
no animals exhibited BrdU incorporation in the CA1 re-
gion of the hippocampus, where obvious neuronal loss
occurs in AblPP/tTA mice. However, extensive labeling
of the olfactory bulb occurred in mice in cohort A, with
somewhat less labeling in cohort B, and the least amount
of labeling occurred in cohort C (Figure 2). These results
indicated that DNA replication, indicating cell cycle acti-
vation, is a very early and transient event in AblPP/tTA
mice and seems to be limited to the olfactory bulb. The
lack of BrdU labeling in cohort C indicates that the cells
that undergo DNA replication in the early stages of c-
Abl activation are lost with time. However, there does
not appear to be an increase in DNA replication or ex-
pression of cell cycle proteins in pyramidal neurons in
the CA1, as no cells in this region were found to be
positive for BrdU, indicating that a separate process may
be at work in that population of neurons.
Interferon signaling pathways in the AblPP/tTA mouse
Expression of interferon signaling genes was strongly
upregulated in AblPP/tTA mouse forebrain at both 2
and 4 weeks off doxycyline. Table 4 lists fold change
values for interferon signaling genes in AblPP/tTA mice.
Interestingly, despite the strong induction of genes
downstream of interferons α, β, and γ, there were no sig-
nificant changes in gene expression of interferons them-
selves. In order to confirm these results, we selected six
genes in the interferon signaling pathway and performed
qPCR on the hippocampus and cortex of AblPP/tTA
mice 2 and 4 weeks off doxycycline. The qPCR analysis
revealed that there was strong upregulation of the six
genes that were downstream of the interferons, but no
significant upregulation of interferons themselves (Fig-
ure 3). IP10, IFIT3, IRF1, Isg15, PSMB8, and STAT1
were all significantly upregulated in AblPP/tTA mouse
cortex at 4 weeks off doxycyline, and all these genes ex-
cept IP10 were also significantly upregulated in the
hippocampus. Despite the lack of statistical significance,
IP10 does trend toward increased levels in the hippo-
campus at 4 weeks off doxycycline. The qPCR data indi-
cate that the induction of interferon stimulated genes
increases with time off doxycyline.
We confirmed that STAT1, a key signaling molecule
in the interferon pathway, is upregulated on a protein
level in AblPP/tTA mouse forebrain by immunoblotting.
Schlatterer et al. Journal of Neuroinflammation 2012, 9:208 Page 4 of 13
http://www.jneuroinflammation.com/content/9/1/208
Table 3 Cell cycle-related genes induced in AblPP/tTA mice at 2 weeks off doxycycline
Fold-change Unique ID GeneBank Accession Gene symbol Description
5.13 7200044 NM_007631 Ccnd1 Mus musculus cyclin D1 (Ccnd1), mRNA.
5.04 5690441 NM_007631 Ccnd1 Mus musculus cyclin D1 (Ccnd1), mRNA.
4.34 20364 NM_007631 Ccnd1 Mus musculus cyclin D1 (Ccnd1), mRNA.
4.03 670739 NM_175659 Hist1h2ah Mus musculus histone cluster 1, H2ah (Hist1h2ah), mRNA.
4.03 3130609 NM_178183 Hist1h2ak Mus musculus histone cluster 1, H2ak (Hist1h2ak), mRNA.
3.85 3520717 NM_178188 Hist1h2ad Mus musculus histone cluster 1, H2ad (Hist1h2ad), mRNA.
3.85 1470341 NM_175659 Hist1h2ah Mus musculus histone cluster 1, H2ah (Hist1h2ah), mRNA.
3.59 5490193 NM_178182 Hist1h2ai Mus musculus histone cluster 1, H2ai (Hist1h2ai), mRNA.
3.58 4250711 NM_175661 Hist1h2af Mus musculus histone cluster 1, H2af (Hist1h2af), mRNA.
3.46 6510253 NM_178185 Hist1h2ao Mus musculus histone cluster 1, H2ao (Hist1h2ao), mRNA.
3.28 7200519 NM_007681 Cenpa Mus musculus centromere protein A (Cenpa), mRNA.
3.27 7160253 NM_178188 Hist1h2ad Mus musculus histone cluster 1, H2ad (Hist1h2ad), mRNA.
3.1 4610129 NM_178184 Hist1h2an Mus musculus histone cluster 1, H2an (Hist1h2an), mRNA.
2.94 1580088 NM_009829 Ccnd2 Mus musculus cyclin D2 (Ccnd2), mRNA.
2.9 1260324 NM_009829 Ccnd2 Mus musculus cyclin D2 (Ccnd2), mRNA.
2.77 6060379 NM_007659 Cdc2a Mus musculus cell division cycle 2 homolog A (S. pombe) (Cdc2a), mRNA.
2.77 1050170 NM_013538 Cdca3 Mus musculus cell division cycle associated 3 (Cdca3), mRNA.
2.76 4610722 NM_023223 Cdc20 Mus musculus cell division cycle 20 homolog (S. cerevisiae) (Cdc20), mRNA.
2.61 6450634 NM_026560 Cdca8 Mus musculus cell division cycle associated 8 (Cdca8), mRNA.
2.52 2190164 NM_172301 Ccnb1 Mus musculus cyclin B1 (Ccnb1), mRNA.
2.51 4250403 NM_011623 Top2a Mus musculus topoisomerase (DNA) II alpha (Top2a), mRNA.
2.41 4390228 NM_023223 Cdc20 Mus musculus cell division cycle 20 homolog (S. cerevisiae) (Cdc20), mRNA.
2.34 630446 NM_183417 Cdk2 Mus musculus cyclin-dependent kinase 2 (Cdk2), transcript variant 1, mRNA.
2.33 520427 NM_011121 Plk1 Mus musculus polo-like kinase 1 (Drosophila) (Plk1), mRNA.
2.15 4570088 NM_023223 Cdc20 Mus musculus cell division cycle 20 homolog (S. cerevisiae) (Cdc20), mRNA.
2.12 1110390 NM_178182 Hist1h2ai Mus musculus histone cluster 1, H2ai (Hist1h2ai), mRNA.
2.09 5820653 NM_175661 Hist1h2af Mus musculus histone cluster 1, H2af (Hist1h2af), mRNA.
2.05 70546 NM_178186 Hist1h2ag Mus musculus histone cluster 1, H2ag (Hist1h2ag), mRNA.
2.01 7550156 NM_172301 Ccnb1 Mus musculus cyclin B1 (Ccnb1), mRNA.
2.01 6860463 NM_009870 Cdk4 Mus musculus cyclin-dependent kinase 4 (Cdk4), mRNA.
1.77 1740039 NM_016756 Cdk2 Mus musculus cyclin-dependent kinase 2 (Cdk2), transcript variant 1, mRNA.
1.69 610717 NM_007632 Ccnd3 Mus musculus cyclin D3 (Ccnd3), transcript variant 1, mRNA.
1.61 1820274 NM_175384 Cdca2 Mus musculus cell division cycle associated 2 (Cdca2), mRNA.
1.6 1500446 NM_026560 Cdca8 Mus musculus cell division cycle associated 8 (Cdca8), mRNA.
1.58 4920148 NM_013538 Cdca3 Mus musculus cell division cycle associated 3 (Cdca3), mRNA.
1.46 6770286 AK077367 Ccnd2 Mus musculus cyclin D2 (Ccnd2), mRNA.
1.4 770162 NM_177733 E2f2 Mus musculus E2F transcription factor 2 (E2f2), mRNA.
1.37 1570754 NM_023223 Cdc20 Mus musculus cell division cycle 20 homolog (S. cerevisiae) (Cdc20), mRNA.
1.33 6550164 NM_177733 E2f2 Mus musculus E2F transcription factor 2 (E2f2), mRNA.
1.28 2000440 NM_183417 Cdk2 Mus musculus cyclin-dependent kinase 2 (Cdk2), transcript variant 1, mRNA.
1.26 4920468 NM_028023 Cdca4 Mus musculus cell division cycle associated 4 (Cdca4), mRNA.
1.24 7160066 NM_028023 Cdca4 Mus musculus cell division cycle associated 4 (Cdca4), mRNA.
1.23 3870112 NM_183417 Cdk2 Mus musculus cyclin-dependent kinase 2 (Cdk2), transcript variant 1, mRNA.
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Additionally, STAT1 expression is not only upregulated,
but the protein itself is activated by phosphorylation at
Y701 and Y727 (Figure 4). Phosphorylation of tyrosine
701 on STAT1 activates the protein, and phosphoryl-
ation of this site is necessary for STAT1 dimerization
and translocation into the nucleus [31]. STAT1 signals
remain high and seem to increase at 4 weeks off doxycy-
line, indicating that the interferon signaling pathway ac-
tivation in AblPP/tTA mice is most likely not a transient
event.
Interferon signaling is upregulated in neurons of the CA1
region of the hippocampus
In order to determine the cell type that demonstrates an
increased expression of STAT 1, immunohistochemistry
and double-labeling experiments were performed. In
Figure 5, we show that STAT1 is elevated in neurons in
the CA1 region of the hippocampus in AblPP/tTA mice,
and that STAT1 co-localizes with the neuronal marker
NeuN. These data indicate that STAT1 expression is
induced in neurons themselves. Intriguingly, the STAT1
Figure 1 Cell cycle activation in the AblPP/tTA mouse. Western blotting of wild-type versus AblPP/tTA mouse forebrain homogenates. Cyclin
B1 and Cdk4 levels are elevated in mice expressing consitutively active c-Abl for 2 weeks, but not 4 weeks, consistent with increased mRNA levels
(Table 3). Polo-like kinase (PLK1) levels were elevated at 2 and 4 weeks, but mRNA levels were only elevated at 2 weeks.
Figure 2 Cell cycle activation occurs in the olfactory bulb but not in the CA1 region of the hippocampus in AblPP/tTA mice and
decreases with time. Bromodeoxyuridine (BrdU) labeling of wild-type versus AblPP/tTA mice. Cohort A = BrdU labeling at 2 weeks, euthanized at
2 weeks; Cohort B = BrdU labeling at 4 weeks, euthanized at 4 weeks; Cohort C = BrdU labeling at 2 weeks, euthanized at 6 weeks. Scalebars:
Dentate, Olfactory bulb = 400 μm, CA1= 800 μm.
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Table 4 Interferon related genes increased at 2 and 4 weeks off doxicycline
Fold Change Unique ID GeneBank Accession Gene symbol Description
2 weeks 4 weeks
9.25 9.29 460221 XM_001472500 Isg15 PREDICTED: Mus musculus hypothetical
protein LOC100038882 (LOC100038882), mRNA.
6.23 3.27 160463 NM_010708 Lgals3bp Mus musculus lectin, galactoside-binding,
soluble, 3 binding protein (Lgals3bp), mRNA.
5.59 2.19 3840292 NM_010509 Ifitm3 Mus musculus interferon induced
transmembrane protein 3 (Ifitm3), mRNA.
5.07 3 2570095 NM_010724 Psmb8 Mus musculus proteasome (prosome, macropain)
subunit, beta type 8 (large multifunctional
peptidase 7) (Psmb8), mRNA.
5.05 2.56 1400041 NM_018734 Gbp2 Mus musculus guanylate binding protein 2 (Gbp2), mRNA.
5.02 4.24 1580528 NM_011909 Usp18 Mus musculus ubiquitin specific peptidase 18 (Usp18), mRNA.
4.89 3.63 7510020 NM_010501 Ifit3 Mus musculus interferon-induced protein with
tetratricopeptide repeats 3 (Ifit3), mRNA.
4.8 3.08 6760390 NM_010387 H2-D1 Mus musculus histocompatibility 2, D region locus 1 (H2-D1), mRNA.
4.47 4.23 4830010 NM_011854 Oasl2 Mus musculus 20-50 oligoadenylate synthetase-like 2 (Oasl2), mRNA.
4.13 2.96 60553 NM_018734 Gbp3 Mus musculus guanylate nucleotide binding protein 3 (Gbp3), mRNA.
3.98 3.67 5270398 NM_008332 Ifit2 Mus musculus interferon-induced protein with tetratricopeptide
repeats 2 (Ifit2), mRNA.
3.04 1.52 3940639 NM_027450 Glipr2 Mus musculus GLI pathogenesis-related 2 (Glipr2), mRNA.
2.96 1.62 4830543 NM_023065 Ifi27 Mus musculus interferon, alpha-inducible protein 27 (Ifi27), mRNA.
2.93 1.45 430167 NM_008534 Ly86 Mus musculus lymphocyte antigen 86 (Ly86), mRNA.
2.62 1.63 3140209 NM_013655 Cxcl10 Mus musculus chemokine (C-X-C motif) ligand 10 (Cxcl10), mRNA.
2.59 1.67 2230386 NM_008348 Iigp2 Mus musculus interferon inducible GTPase 2 (Iigp2), mRNA.
2.5 1.81 830762 NM_026030 Eif2ak2 Mus musculus eukaryotic translation initiation factor 2-alpha kinase
2 (Eif2ak2), mRNA.
2.47 1.94 6660634 NM_008390 Irf1 Mus musculus interferon regulatory factor 1 (Irf1), mRNA.
2.14 1.35 6660176 NM_213659 Stat3 Mus musculus signal transducer and activator of transcription 3
(Stat3), transcript variant 1, mRNA.
2.08 1.94 2000373 NM_009825 Serping1 Mus musculus serine (or cysteine) peptidase inhibitor, clade G,
member 1 (Serping1), mRNA.
2.06 1.33 3780736 NM_001001892 H2-K1 Mus musculus histocompatibility 2, K1, K region (H2-K1), transcript
variant 1, mRNA.
1.93 1.39 130598 NM_011852 Oas1g Mus musculus 20-50 oligoadenylate synthetase 1 G (Oas1g), mRNA.
1.9 1.49 5720255 NM_201394 Pld4 Mus musculus phospholipase D family, member 4 (Pld4), mRNA.
1.86 1.43 4120014 NM_008330 Ifi35 Mus musculus interferon-induced protein 35 (Ifi35), mRNA.
1.85 1.48 4150050 NM_133779 Pigt Mus musculus phosphatidylinositol glycan anchor biosynthesis,
class T (Pigt), mRNA. XM_922599
1.84 1.87 3060482 NM_008394 Irf9 Mus musculus interferon regulatory factor 9 (Irf9), mRNA.
1.81 1.29 2100484 NM_025928 Plxnb2 PREDICTED: Mus musculus plexin B2, transcript variant 13
(Plxnb2), mRNA.
1.76 1.84 240725 NM_009283 Stat1 Mus musculus signal transducer and activator of transcription 1
(Stat1), mRNA.
1.72 2.11 520278 NM_024263 Mx2 Mus musculus myxovirus (influenza virus) resistance 2 (Mx2), mRNA.
1.67 1.4 5870093 NM_011530 Tap1 Mus musculus transporter 1, ATP-binding cassette, sub-family B
(MDR/TAP) (Tap1), mRNA.
1.64 1.37 6770114 NM_001012236 Trem2 Mus musculus triggering receptor expressed on myeloid cells 2
(Trem2), mRNA.
1.61 1.29 3780279 NM_026116 Bax Mus musculus Bcl2-associated X protein (Bax), mRNA.
1.55 1.32 5130139 NM_009369 Tgfb1 Mus musculus transforming growth factor, beta 1 (Tgfb1), mRNA.
1.55 1.22 1090139 NM_008332 Ifi47 Mus musculus interferon gamma inducible protein 47 (Ifi47), mRNA.
1.53 1.3 3060450 NM_011854 Oas2 Mus musculus 20-50 oligoadenylate synthetase 2 (Oas2), mRNA.
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staining co-localizes to the CA1 region of the hippocam-
pus, which experiences severe neuronal loss in aged
AblPP/tTA mice.
Discussion
It has been shown previously that c-Abl activation in adult
neurons leads to neurodegeneration and neuroinflamma-
tion [8]. However, the mechanism by which c-Abl activa-
tion leads to these consequences remains unknown. In the
work presented here, we show a correlation between c-
Abl activation and the induction of two cell signaling
pathways. First, transient but strong expression of cell
cycle related proteins and DNA replication occurs in the
olfactory bulb. Second, induction of interferon signaling
genes occurs in the hippocampus, and the major signaling
molecule of this pathway, STAT1, is upregulated in neu-
rons in the CA1 region.
The first pathway examined was the cell cycle. The data
show that expression of cell cycle related proteins and
DNA replication does occur in AblPP/tTA mice, indicat-
ing that the cell cycle is activated, at least partially through
S-phase. However, these findings do not localize to the
CA1 region of the hippocampus. This suggests that aber-
rant cell cycle activation does not play a role in neuronal
death observed in pyramidal neurons in CA1 of AblPP/
tTA mice. Increased BrdU incorporation occurred mainly
in the olfactory bulb, although BrdU-labeled cells were
also found along a pathway anatomically consistent with
the rostral migratory stream (data not shown). There is
abundant expression of AblPP in the olfactory bulb [8].
Interestingly, BrdU labeling occurred in cells in the ol-
factory bulb when BrdU was administered at 2 weeks off
doxycyline and mice were euthanized immediately, but
BrdU labeling precipitously decreased when mice were
administered BrdU at 2 weeks off doxycyline then aged
for a further 4 weeks (Figure 2). Therefore, the cells that
undergo DNA replication in the olfactory bulb of AblPP/
tTA mice do not appear to survive for an extended period
of time. The number of cells labeled in the dentate gyrus
of AblPP/tTA mice also appears to decrease. This raises
the possibility that c-Abl strongly induces DNA replica-
tion and possibly aberrant cell cycle activation at early
time points, but that the cells that undergo this process
may have impaired survival and decreased ability to repli-
cate DNA as the mice age. BrdU labeling experiments per-
formed on older AblPP/tTA mice support this hypothesis.
In mice that were administered BrdU for 5 days prior to
euthanization at 11 weeks off doxycyline, no labeling of
the dentate gyrus occurred (Additional file 1: Figure S1).
The second pathway that we examined was interferon
signaling. Our findings that interferon stimulated genes
are induced in the presence of active c-Abl are consist-
ent with previous reports showing that P210 BCR/Abl
can induce expression of interferon responsive genes, in-
cluding OAS1, IFIT1, IFI16, ISGF3G, and STAT1, in
U937 cells in culture [32]. Also consistent with other
studies, we find no evidence of significant induction of
interferons themselves [32]. While other groups have fo-
cused on myeloid cells, this is the first evidence that
interferon signaling pathways are induced by c-Abl acti-
vation in adult neurons in vivo. These data suggest that
the AblPP/tTA mouse model will be useful to investigate
the role of interferon signaling in neurodegeneration and
neuroinflammation.
Given that STAT1, the major signaling molecule
downstream of the interferons, was activated in the same
Table 4 Interferon related genes increased at 2 and 4 weeks off doxicycline (Continued)
1.49 1.29 6590653 NM_008320 Irf7 Mus musculus interferon regulatory factor 7 (Irf7), mRNA.
1.47 1.49 5870398 NM_011970 Psmb10 Mus musculus proteasome (prosome, macropain) subunit, beta
type 10 (Psmb10), mRNA.
1.45 1.25 460435 NM_016660 Hmg20b Mus musculus high mobility group 20 B (Hmg20b), mRNA.
1.42 1.22 290494 XM_894155 BC004012 Mus musculus Nadk NAD kinase, mrNA.
1.4 1.42 6220594 NM_213659 Stat2 Mus musculus signal transducer and activator of transcription 2
(Stat2), mRNA.
1.4 1.37 4810072 NM_008490 Lcat Mus musculus lecithin cholesterol acyltransferase (Lcat), mRNA.
1.39 1.42 2450554 NM_011175 Lgi4 Mus musculus leucine-rich repeat LGI family, member 4 (Lgi4), mRNA.
1.38 1.24 2480373 NM_026836 Taf10 Mus musculus TAF10 RNA polymerase II, TATA box binding protein
(TBP)-associated factor (Taf10), mRNA.
1.33 1.39 6550376 NM_008529 Ly6e Mus musculus lymphocyte antigen 6 complex, locus E (Ly6e), mRNA.
1.33 1.21 540411 NM_177663 Isg20 Mus musculus interferon-stimulated protein (Isg20), mRNA.
1.31 1.42 7210687 NM_007471 Apoe Mus musculus apolipoprotein E (Apoe), mRNA.
1.26 1.22 990129 NM_026960 Grwd1 Mus musculus glutamate-rich WD repeat containing 1 (Grwd1), mRNA.
1.24 1.19 5870255 NM_028162 Tbc1d10a Mus musculus TBC1 domain family, member 10a (Tbc1d10a), mRNA.
1.22 1.49 4890626 NM_008879 Lcn2 Mus musculus lipocalin 2 (Lcn2), mRNA.
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Figure 3 (See legend on next page.)
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anatomical region in which neurodegeneration occurs in
AblPP/tTA mice, it is possible that STAT1 activation
and interferon signaling play a role in c-Abl induced
pathology in the CA1 region of the hippocampus.
STAT1 activation has been associated with death in ter-
minally differentiated cells and has been shown to play a
role in apoptosis in response to TNFα treatment in cell
culture [33]. Ischemia-reperfusion induced death is
enhanced by STAT1 in cardiac myocytes, which, like
neurons, are terminally differentiated [34,35]. Treatment
of mice with paraquat, a toxin that induces selective loss
of dopaminergic neurons, resulted in increased expres-
sion of STAT1 mRNA in the substantia nigra pars com-
pact in a time course corresponding to dopaminergic
neuronal loss [36]. Activated (pY701) STAT1 is upregu-
lated in rat brain during focal cerebral ischemia-
reperfusion experiments and localizes to the core of
lesions, indicating that it may play a role in cell death
during ischemia-reperfusion [37].
The role of other interferon signaling genes in neuro-
degenerative and neuroinflammatory diseases is less
clear. Interferon signaling has been associated with cell
loss, and, while we observe no significant increases in
expression of interferons themselves, it is reasonable to
assume that activation of downstream signaling mole-
cules could have a similar effect as treatment with inter-
ferons themselves. In SHSY5Y cells, interferon β
treatment results in apoptosis, and pretreatment of
interferon β treated cells with P6, a pan-JAK inhibitor
that results in downstream inhibition of STATs, led to
decreased caspase 9, 7, and 3 cleavage and decreases in
PARP expression, resulting in rescue of the apoptotic
phenotype [38]. In primary neuronal cultures, long-term
treatment with interferon β led to loss of neuritic pro-
cesses and increased pY701 STAT1 and caspase 3 levels
[38], and interferon γ knockout mice exhibited less neur-
onal loss in response to paraquat treatment, suggesting
that interferon γ signaling may play a role in paraquat-
induced neuronal loss [36]. Interferon regulatory factor
1 is thought to play a role in neuronal death in response
to ischemia [39]. However, interferon regulatory factors
3 and 7 have been shown to be necessary for neuropro-
tection in multiple preconditioning paradigms for ische-
mia reperfusion injury [40].
While the precise role of cell cycle activation and
interferon signaling in response to c-Abl activation in
neurons remains unclear, we have demonstrated that c-
Abl activation leads to an early, transient induction of
cell cycle activation in the olfactory bulb and rostral mi-
gratory stream and to induction of interferon stimulated
genes without (or prior to) induction of interferon ex-
pression. One interpretation of these data is that the cell
cycle activation observed may be due to a transient stimu-
lation of neurogenesis, although further studies would be
necessary to confirm this hypothesis. Interestingly, there is
evidence that interferon signaling downstream of c-Abl
Figure 4 Levels of activated STAT1 are increased in AblPP/tTA mice 2 and 4 weeks off doxycycline. Western blot membranes were
probed with antibodies to STAT1 pY701, STAT pS727, STAT1, and β-actin loading control. STAT1 pY701, STAT1 pS727, and STAT1 total protein
levels were elevated in AblPP mice expressing constitutively active c-Abl for 2 and 4 weeks compared with wild-type controls.
(See figure on previous page.)
Figure 3 Expression of interferon signaling genes is upregulated in AblPP/tTA mice, but expression of interferons themselves are not.
Quantitative real-time PCR of AblPP/tTA mouse cortex and hippocampus versus wild-type mouse cortex and hippocampus at 2 and 4 weeks off
doxycyline. *P< 0.05, **P< 0.01.
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Figure 5 STAT1 expression occurs in neurons of the CA1 region of the hippocampus in AblPP/tTA mice prior to neuronal loss.
(A-E) STAT1 immunohistochemistry of the CA1 region of an AblPP/tTA mouse expressing constitutively active c-Abl for 3 weeks (B,D,E) versus
wild-type control (A,C). (F,G) STAT1pY701 immunohistochemistry the CA1 region of a wild-type mouse (F) versus an AblPP/tTA mouse 3 weeks
off doxycyline (G). Cells positive for STAT1 pY701 are indicated with arrows. (H,I) Double labeling with NeuN (green) and total STAT1 (red) in
wild-type (panel H) and AblPP mice expressing constitutively active c-Abl for 2 weeks (panel I). Scalebars: A,B = 2 mm; C,D,F,G= 800 μm; E=400 μm.
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may have a role to play in stimulation of neurogenesis, as
interferon treatment in 3xTg mice lead to increased
neurogenesis in addition to increased severity of amyloid
pathology and inflammation [41].
The localization of STAT1 activation in the CA1 re-
gion of the hippocampus, where severe neuronal loss
and neuroinflammation occurs in aged AblPP/tTA mice,
suggests that c-Abl induced expression of interferon sig-
naling genes may play a role in the development of neu-
roinflammation and neurodegeneration observed in
these mice. Further studies are necessary to determine
whether STAT1 and other interferon signaling genes
play a causative or protective role in neurodegeneration
and neuroinflammation in AblPP/tTA mice. However,
these data show a correlation between sites of neurode-
generation and gliosis and interferon signaling. Overall,
these data show that the AblPP/tTA mouse may be an
excellent model of sterile neuroinflammation in the con-
text of neurodegeneration and could be used to elucidate
the role of interferon signaling in neuroinflammatory
and neurodegenerative disorders.
Additional file
Additional file 1: Figure S1. Neurogenesis is apparently lost in AblPP/
tTA mice with age. Bromodeoxyuridine (BrdU) labeling of the dentate
gyrus of wild-type versus AblPP/tTA mice at 11 weeks off doxycyline.
Scalebars = 400 μm. The localization of BrdU labeled cells is consistent
with the distribution of neuroblasts.
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